Patient characteristics, MRI examination, and dopaminergic drug response in clinical possible Parkinson's disease

Journal of Geriatric Psychiatry and Neurology

Volumn 9, Issue 4, 1996, Pages 157-163

  Larsen, Jan P ^a   Ødegaard, Helge ^a   Tandberg, Elise ^a   Hødnebø, Anne ^a   Aarsland, Dag ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN ATROPHY; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG RESPONSE; FEMALE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; NORWAY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROBABILITY;

EID: 0030478540     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198879600900401     Document Type: Article

References (25)

1. Marsden CD. Parkinson's disease. Lancet 1990; 335:948-952.
2. Quinn NP, Husain FA. Clinical algorithm. Parkinson's disease. Br Med J 1986; 293:379-382.
3. Poewe WH. Clinical differential diagnosis of Parkinson's disease. In: Rinne UK, Nagatsu T, Horowski R, eds. International Workshop Berlin, Parkinson's disease. Bussum: Medicom, 1990:174-181.
4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of the clinical diagnosis of Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184.
5. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991; 18:275-278.
6. Gibb WRG, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. J Neuropathol Appl Neurobiol 1989; 15:27-44.
7. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42:1142-1146.
8. Larsen JP, Dupont E, Tandberg E. The clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994; 84:242-251.
9. Olanow CD. Magnetic resonance imaging in parkinsonism. Neurol Clin 1992; 10:405-420.
10. Stern MB, Braffman BH, Skolnick BE, et al. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology 1989; 39:1524-1526.
11. Barbeau A, Roy M. Six year results of treatment with levodopa plus benzerazide in Parkinson's disease. Neurology 1976; 26:399-404.
12. Hughes AJ, Colosimo C, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992; 55:1009-1013.
13. Turjanski N, Fernandez W, Lees AJ. The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1993; 56:771-775.
14. Tandberg E, Larsen JP, Nessler EG, et al. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Movement Disord 1995; 10:541-548.
15. Quinn NP. Multiple system atrophy -the nature of the beast. J Neurol Neurosurg Psychiatry 1989; (Spec Suppl):78-79.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the mental state of patients for the clinician. J Psychiatry Res 1975; 12:189-198.
17. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A, eds. Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Health Care Information, 1987:153-163.
18. Hoehn MH, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442.
19. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third symposium on Parkinson's disease. Edinburgh: E&S Livingstone, 1969:152-157.
20. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:322-389.
21. DuGuid JR, De La Paz R, DeGrott J. Magnetic resonance imaging of the midbrain in Parkinson's disease. Ann Neurol 1986; 20:744-747.
22. Watts RL, Mandir AS. Quantitative methods of evaluating Parkinson's disease. In: Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's disease. New Jersey: Parthenon Publishing Group Ltd., 1992:13-32.
23. Schoenberg BS, Andersen AW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985; 35:841-845.
24. Olanow CW, Alberts M, Djang W, Stajich J. MR imaging of putamenial iron predicts response to dopaminergic therapy in parkinsonian patients. In: Dostert P, Riederer P, Strolin G, et al, eds. Early markers in Parkinson's and Alzheimer's diseases. Austria: Springer Verlag, 1990:99-109.
25. Gancher ST. Pharmacology of Parkinson's disease. In: Huber SJ, Cummings JL, eds. Parkinson's diseases. Neurobehavioral aspects. New York: Oxford University Press, 1992: 273-287.